PATIENTS & CARE PARTNERS Putting patients and their families first
We are rethinking care and how it is delivered to help patients and families impacted by brain health disorders.
News The latest from Sage
press releases & statements
events & presentations
Pipeline
(zuranolone) CIV
- Postpartum Depression
(brexanolone) CIV injection
- Postpartum Depression
(SAGE-718)
- Huntington’s Disease Cognitive Impairment
-
SAGE-324***GABA Hypofunction
-
SAGE-689Acute GABA Hypofunction
-
SAGE-421NMDA Hypofunction
-
SAGE-319GABA Hypofunction
*Collaboration Partners: Biogen Inc. and Shionogi for zuranolone
**Sage plans to discontinue commercial availability of ZULRESSO in the U.S. as of December 31, 2024.
***In July 2024, we announced discontinuation of clinical development of SAGE-324 in ET. Sage
is
evaluating next steps, if any, for other potential indications.
Please refer to the
U.S.
Prescribing Information for ZULRESSO
and the
U.S.
Prescribing Information for ZURZUVAE
Safety and efficacy for investigational uses or compounds have not been established. There is no
guarantee that the outcome of these studies will be positive or result in approval by a health
authority.